Development and validation of a bioanalytical method to quantify povorcitinib in human skin with clinical application

This study provides the first systemic evaluation of human skin homogenization parameters and a direct comparison of wet and dry approaches. The validated dry homogenization method enabled accurate and reproducible quantification of povorcitinib in skin biopsies from a phase I clinical study and offers a robust framework for quantifying a broad range of analytes in human skin tissues.<b>Clinical trial registration:</b> https://www.clinicaltrials.gov/study/NCT06505265 [clinicaltrials.gov] identifier is NCT06505265.